Table 1 Characteristics of stage II–III CRC patients according to quartiles of circulating C-reactive protein levels, Seattle CCFR 1998–2007.

From: Association between post-treatment circulating biomarkers of inflammation and survival among stage II–III colorectal cancer patients

Characteristicsa

C-reactive protein

Total (N = 306)

Q1 (N = 78)

Q2 (N = 76)

Q3 (N = 76)

Q4 (N = 76)

 

Age at diagnosis (years), mean (SD)

53.1 (13.0)

54.8 (12.9)

56.5 (10.9)

56.3 (11.4)

55.2 (12.1)

Female

40 (51)

39 (51)

39 (51)

39 (51)

157 (51)

Body mass index (kg/m2)b, mean (SD)

24.8 (4.1)

27.2 (4.5)

29.0 (5.9)

29.5 (5.9)

27.6 (5.5)

  Underweight/normal

43 (55)

24 (32)

18 (24)

16 (21)

101 (33)

  Overweight

27 (35)

36 (47)

29 (38)

26 (34)

118 (39)

  Obese

8 (10)

16 (21)

29 (38)

34 (45)

87 (28)

Ever-smokerc

46 (59)

43 (57)

41 (54)

55 (72)

185 (60)

Regular use of NSAIDsc

36 (46)

31 (41)

39 (51)

38 (50)

144 (47)

Diagnosed with diabetesc

4 (5)

11 (14)

10 (13)

7 (9)

32 (10)

Diagnosed with high cholesterolc

17 (22)

22 (29)

28 (37)

20 (26)

87 (28)

Family history of CRCc

9 (12)

13 (17)

11 (14)

13 (17)

46 (15)

Stage at diagnosis

  II

41 (53)

32 (42)

33 (43)

37 (49)

143 (47)

  III

37 (47)

44 (58)

43 (57)

39 (51)

163 (53)

Tumour location

  Colon

51 (65)

54 (71)

49 (64)

58 (76)

212 (69)

  Rectum

27 (35)

22 (29)

27 (36)

17 (22)

93 (30)

Had surgery

72 (92)

71 (93)

71 (93)

70 (92)

284 (93)

Had radiation

17 (22)

17 (22)

21 (28)

18 (24)

73 (24)

Had chemotherapy

61 (78)

62 (82)

61 (80)

57 (75)

241 (79)

  Single regimen

29 (37)

24 (32)

29 (38)

29 (38)

111 (36)

  Multiple regimens

25 (32)

36 (47)

31 (41)

24 (32)

116 (38)

  Unknown regimen

7 (9)

2 (3)

1 (1)

4 (5)

14 (5)

MSI

  MSS/MSI-low

47 (60)

43 (57)

55 (72)

44 (58)

189 (62)

  MSI-high

11 (14)

15 (20)

10 (13)

15 (20)

51 (17)

  Missing

20 (26)

18 (24)

11 (15)

17 (22)

66 (22)

KRAS

  Wild type

40 (51)

48 (63)

45 (59)

48 (63)

181 (59)

  Mutant

19 (24)

17 (22)

22 (29)

11 (14)

69 (23)

  Missing

19 (24)

11 (15)

9 (12)

17 (22)

56 (18)

BRAF

  Wild type

57 (73)

55 (72)

61 (80)

49 (64)

222 (73)

  Mutant

5 (6)

10 (13)

6 (8)

11 (14)

32 (10)

  Missing

16 (21)

11 (15)

9 (12)

16 (21)

52 (17)

CIMP

  CIMP-low/no

37 (47)

40 (53)

52 (68)

42 (55)

171 (56)

  CIMP-high

11 (14)

12 (16)

7 (9)

11 (14)

41 (13)

  Missing

30 (39)

24 (32)

17 (22)

23 (30)

94 (31)

Plasma storage time (years), mean (SD)

16.8 (2.8)

16.7 ((2.6)

17.0 (2.6)

17.1 (2.7)

16.9 (2.7)

Time between diagnosis and blood draw (years), mean (SD)

1.5 (0.5)

1.7 (0.6)

1.6 (0.5)

1.6 (0.5)

1.6 (0.5)

  1. CIMP CpG island methylator phenotype, MSI microsatellite instability, MSS microsatellite stability, NSAIDs non-steroidal anti-inflammatory drugs, Q1 1st quartile, Q2 2nd quartile, Q3 3rd quartile, Q4 4th quartile, SD standard deviation.
  2. aN (%) unless otherwise specified.
  3. bBody mass index was asked at a reference date, defined as 2 years before baseline interview (~1 year before diagnosis).
  4. cQuestion on smoking was assessed as “Have you ever smoked at least one cigarette a day for 3 months or longer”; regular use of NSAIDs was defined as ever use of aspirin- or ibuprofen-based medications at least twice a week for more than a month; diagnosis of diabetes and high cholesterol was assessed as “Has a doctor ever told you that you had diabetes, also known as diabetes mellitus (not including gestational diabetes/diabetes you had only during pregnancy)?” and “Has a doctor ever told you that you had high cholesterol?”, respectively; family history is defined as having at least one first-degree relatives diagnosed with CRC.
Back to article page